Step 1 topics → Endocrine → Prolactinoma

Prolactinoma

USMLE Step 1 trap: Selects surgery as first-line for prolactinoma instead of dopamine agonist therapy. Dopamine agonists (cabergoline or bromocriptine) are first-line for prolactinoma because dopamine normally inhibits prolactin secretion; surgery is reserved for drug intolerance or resistance.

Prolactinoma is the most common functional pituitary adenoma, and USMLE Step 1 tests it from three angles, each with its own trap. Students consistently select surgery as first-line when dopamine agonists (cabergoline) are definitively first-line and often shrink the tumor without an OR. They assume any elevated prolactin means prolactinoma, missing drug causes, primary hypothyroidism, and stalk compression. And they miss why men present so much later than women — galactorrhea and amenorrhea are obvious; decreased libido and erectile dysfunction in men are vague and get ignored until the tumor causes visual field defects.

The exam tests this from three distinct angles. First, presentation — and this is where students consistently slip up. Women present early because galactorrhea and amenorrhea are impossible to miss; men present late because there's no equivalent obvious symptom, so the adenoma grows into a macroadenoma before anyone notices. By the time a man shows up, he's got headaches, bitemporal hemianopsia from optic chiasm compression, and sexual dysfunction from suppressed testosterone. Second, Step 1 will give you a vignette with elevated prolactin and ask you to identify the cause — which is often NOT a prolactinoma. Third, it tests management, specifically whether you reflexively pick surgery when you shouldn't.

The biggest traps: assuming any elevated prolactin means prolactinoma (it doesn't — you have to rule out drugs, hypothyroidism, pregnancy, and stalk effect first), and assuming surgery is first-line (it isn't — dopamine agonists like cabergoline are). These aren't random facts to memorize; they're logical consequences of the dopamine-prolactin axis that you should be able to derive on the spot.

From real student decks
89%have cards covering this topic
78%have mature cards

Well-covered in most decks — the challenge is retention, not exposure.

Common misconceptions

Common mistake
Wrong: Surgery is the first-line treatment for prolactinoma.
Right: Dopamine agonists (cabergoline or bromocriptine) are first-line for prolactinoma because dopamine normally inhibits prolactin secretion; surgery is reserved for drug intolerance or resistance.
Surgery feels intuitive for a tumor, but prolactinoma is one of the few adenomas where medical therapy is definitively first-line. Because dopamine normally suppresses prolactin, giving a dopamine agonist like cabergoline restores that inhibition — the tumor often shrinks significantly without an OR. Surgery is reserved for patients who can't tolerate the drug, fail to respond, or have acute vision-threatening compression. Selecting surgery first on Step 1 is the classic trap.
Common mistake
Wrong: Prolactinoma presents the same way in men and women.
Right: Women typically present early with galactorrhea and amenorrhea (microadenoma); men present later with mass effects (headache, visual field defects) and sexual dysfunction because symptoms are less obvious.
The sex difference isn't arbitrary — it's about how noticeable the symptoms are. In women, even a small microadenoma causes galactorrhea and disrupts the menstrual cycle, so they seek care early. In men, hyperprolactinemia suppresses testosterone (causing decreased libido and erectile dysfunction), but those symptoms are vague and often attributed elsewhere. By the time a man is diagnosed, the adenoma has usually grown large enough to cause headaches and compress the optic chiasm, producing the classic bitemporal hemianopsia. If your Step 1 vignette describes a man with visual field defects and a pituitary mass, prolactinoma should be high on your list.
Common mistake
Wrong: Any elevated prolactin level confirms a prolactinoma.
Right: Hyperprolactinemia has many causes including primary hypothyroidism (elevated TRH), dopamine-blocking drugs (antipsychotics, metoclopramide), stalk compression, pregnancy, and renal failure, all of which must be excluded before diagnosing prolactinoma.
Elevated prolactin is a lab finding, not a diagnosis. Before calling it a prolactinoma, you must exclude: antipsychotics and metoclopramide (block dopamine receptors, removing tonic inhibition), primary hypothyroidism (elevated TRH directly stimulates prolactin release — always check TSH), pregnancy, and renal failure (decreased clearance). Stalk compression from any non-secreting pituitary mass can also raise prolactin by blocking dopamine delivery. The vignette will often hand you a drug history or a TSH result as the key clue — don't ignore it.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Recognize how prolactinoma presents differently in men vs. women — women get galactorrhea and amenorrhea early (microadenoma); men get mass effects (headache, bitemporal hemianopsia) and sexual dysfunction late (macroadenoma).
  2. Work through the differential for hyperprolactinemia — distinguish prolactinoma from dopamine-blocking drugs (antipsychotics, metoclopramide), primary hypothyroidism (elevated TRH stimulates prolactin), pituitary stalk compression, pregnancy, and renal failure.
  3. Identify first-line treatment: dopamine agonists (cabergoline preferred over bromocriptine) are first-line for prolactinoma; surgery is reserved for drug resistance, intolerance, or acute vision loss.

Can you avoid these mistakes?

A 34-year-old woman has amenorrhea, galactorrhea, and a serum prolactin of 180 ng/mL. MRI shows a 6mm pituitary lesion. What is the first-line treatment, and what is the mechanism of action?
A 45-year-old man presents with decreased libido, erectile dysfunction, and bitemporal hemianopsia. Labs show low testosterone and elevated prolactin. Why did this man present so much later than a woman with the same tumor would have?
A 28-year-old woman on haloperidol for schizophrenia has a prolactin level of 95 ng/mL. Her MRI shows no pituitary mass. What is the most likely cause of her hyperprolactinemia, and what is the mechanism?
A patient with a prolactinoma fails cabergoline therapy and develops worsening visual field defects. What is the next step in management, and why does this indication override the usual preference for medical therapy?

Related topics

Hypothalamic-Pituitary-Gonadal (HPG) Axis Hypothalamic-Pituitary-Adrenal (HPA) Axis Hypothalamic-Pituitary-Thyroid (HPT) Axis Hormone Signaling (Peptide vs Steroid)

See how your Anki deck covers this topic.

Upload your deck for a free audit →